Barclays PLC Provention Bio, Inc. Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$4.52 - $10.57 $112,303 - $262,622	24,846 New	24,846 $263,000
Q4 2021 Feb 14, 2022	SELL	$5.59 - $7.39 $434,247 - $574,077	-77,683 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$5.66 - $8.33 $399,975 - $588,656	70,667 Added 1007.23%	77,683 $497,000
Q2 2021 Aug 13, 2021	BUY	$6.71 - $11.04 $44,943 - $73,945	6,698 Added 2106.29%	7,016 $59,000
Q1 2021 May 13, 2021	BUY	$10.12 - $19.45 $1,244 - $2,392	123 Added 63.08%	318 $3,000
Q4 2020 Feb 11, 2021	SELL	$11.79 - $18.94 $265,852 - $427,078	-22,549 Reduced 99.14%	195 $3,000
Q3 2020 Nov 12, 2020	BUY	$10.34 - $15.2 $235,172 - $345,708	22,744 New	22,744 $292,000
Q1 2020 May 13, 2020	SELL	$5.42 - $17.75 $5 - $17	-1 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$5.84 - $14.9 $22,010 - $56,158	-3,769 Reduced 99.97%	1 $0
Q3 2019 Nov 14, 2019	SELL	$6.83 - $13.0 $27,647 - $52,624	-4,048 Reduced 51.78%	3,770 $26,000
Q2 2019 Aug 14, 2019	BUY	$2.3 - $13.79 $17,981 - $107,810	7,818 New	7,818 $95,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.